Sarepta Therapeutics (SRPT) Says FDA Requests Dystrophin Data

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.

You May Also Be Interested In

• Jackson Financial Inc. (JXN) Mentioned as Short at Bear Cave
• Novo Nordisk and Anthropic announce R&D collaboration
• EMA panel backs Novo Nordisk's Sogroya for children's growth disorder